Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib

NCT01933945 · clinicaltrials.gov ↗

COMPLETED

Status

1676

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

PROCEDURE: TACE (transarterial chemoembolization)
DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer